BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced positive data from an ongoing phase I trial of SGN-35, a proprietary antibody-drug conjugate (ADC) product candidate. Multiple objective responses have been observed at well-tolerated doses of SGN-35 in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive malignancies. The data were reported today at the 7th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
